Pharmacodynamic Effects of Prasugrel Dosing Regimens in Patients on Maintenance Prasugrel Therapy Results of a Prospective Randomized Study by Tello-Montoliu, Antonio et al.
Journal of the American College of Cardiology Vol. 59, No. 19, 2012
© 2012 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00Antiplatelet Therapy
Pharmacodynamic Effects of
Prasugrel Dosing Regimens in
Patients on Maintenance Prasugrel Therapy
Results of a Prospective Randomized Study
Antonio Tello-Montoliu, MD, PHD, Salvatore D. Tomasello, MD, José Luis Ferreiro, MD,
Masafumi Ueno, MD, Naveen Seecheran, MD, Bhaloo Desai, PHD, Murali Kodali, MD,
Ronald K. Charlton, PHD, Lyndon C. Box, MD, Martin M. Zenni, MD, Luis A. Guzman, MD,
Theodore A. Bass, MD, Dominick J. Angiolillo, MD, PHD
Jacksonville, Florida
Objectives The purpose of this study is to assess the pharmacodynamic effects of different prasugrel dosing regimens in
patients on maintenance prasugrel therapy.
Background There are a growing number of patients on chronic prasugrel therapy regimens, leading to questions about the
dosing regimen of prasugrel to administer if percutaneous coronary intervention is required.
Methods This is a prospective pharmacodynamic study in patients (n  64) receiving maintenance prasugrel therapy who
were randomly allocated to a 10 mg, 30 mg, or 60 mg dose of prasugrel. Pharmacodynamic assessments using
multiple assays were conducted at 3 timepoints (baseline and 1 h and 4 h after dosing).
Results Intragroup comparisons showed that a 60 mg dose reduced the platelet reactivity index (PRI) after 1 h (p 
0.004) and 4 h (p  0.001, primary endpoint; p  0.002 between 1 h and 4 h). A 30 mg dose also reduced PRI
levels at 1 h (p  0.006) and 4 h (p  0.001; p  0.044 between 1 h and 4 h). A 10 mg dose was associated
with modest pharmacodynamic effects. Intragroup comparisons showed similar findings with VerifyNow-P2Y12
and light transmission aggregometry. Intergroup comparisons showed that a 60 mg dose achieved lower PRI
levels than 30 mg at 4 h (p  0.05), and a numerical trend toward better pharmacodynamic effects at 1 h
(p  0.171). Intergroup comparisons were similar with VerifyNow-P2Y12, but not light transmission aggregometry.
Conclusions For patients on maintenance prasugrel therapy, a 60 mg dosing strategy is associated with faster and higher
platelet inhibition compared with lower doses, as assessed by P2Y12 specific assays. (Impact of Prasugrel Re-
load on Platelet Aggregation in Patients on Chronic Prasugrel Therapy; NCT01201772) (J Am Coll Cardiol
2012;59:1681–7) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.12.039Dual antiplatelet therapy with aspirin and a P2Y12 receptor
inhibitor is recommended for prevention of ischemic events
in acute coronary syndrome (ACS) patients and patients
undergoing percutaneous coronary interventions (PCI) (1).
Prasugrel is a P2Y12 receptor inhibitor approved for the
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still occur in prasugrel-treated
patients and may, therefore, ne-
cessitate further revascularization
procedures. In addition, many
patients may require subsequent
revascularization due to chronic
progression of their coronary ath-
erosclerotic disease or for a staged
PCI. Therefore, there is a growing
number of patients who are under-
going PCI while on a regimen of
chronic prasugrel therapy. That
has raised concerns with regard to
the optimal dosing of prasugrel in
the peri-PCI period.
Methods
Study design and patient population. This is a prospective,
randomized, open-label study designed to evaluate the phar-
macodynamic effects of different prasugrel dosing regimens in
patients on prasugrel maintenance therapy. Patients were
randomly assigned to 1 of 3 prasugrel dosing regimens in a
1:1:1 fashion: 10 mg, 30 mg, or 60 mg. Prasugrel was
administered as 10 mg tablets (Eli Lilly and Co., Indianapolis,
Indiana). Blood sampling for pharmacodynamic testing was
conducted at 3 timepoints: at baseline, and 1 h and 4 h after
prasugrel dosing. The study design is illustrated in Figure 1.
Patients were followed up to 7 days after completing the study
to assess whether they experienced any adverse events.
Patients were screened at the outpatient clinics of our
institution and considered eligible for the study if they were
between 18 and 74 years of age and were receiving treatment with
prasugrel 10 mg/day for at least 14 days. All patients were
receiving aspirin 81 mg/day. Exclusion criteria for this study
included active bleeding, prior cerebrovascular event, body weight
60 kg, age 75 years, clinical instability after the index event,
use of oral anticoagulation agent, platelet count 100106/l,
emoglobin 10 g/dl, creatinine 2 mg/dl, hepatic enzymes
2.5 times the upper limit of normal, or pregnant/lactating
emale. The study was approved by our institutional review
oard, and all subjects provided written informed consent.
lood sampling and pharmacodynamic tests. Patients
ithheld their dose of prasugrel the morning of their
cheduled visit so that their last maintenance dose of
rasugrel was 18 h to 24 h before baseline blood sampling to
nable determination of trough levels of platelet reactivity.
itrated blood samples were processed by laboratory per-
onnel blinded to treatment assignment. Platelet function
ssays included flow cytometric analysis of the phosphory-
ation status of the vasodilator-stimulated phosphoprotein
VASP) assay (Biocytex, Marseille, France), the VerifyNow
2Y12 (VN-P2Y12) assay (Accumetrics, San Diego, Cali-
ornia), and light transmission aggregometry (LTA
Abbreviations
and Acronyms
ACS  acute coronary
syndrome
LTA  light transmission
aggregometry
PCI  percutaneous
coronary intervention
PRI  platelet reactivity
index
PRU  P2Y12 reaction
units
VASP  vasodilator-
stimulated phosphoprotein
VN-P2Y12  VerifyNow-P2Y12Chrono-Log Corp., Havertown, Pennsylvania]). All assaysere performed according to standard protocols as previ-
usly described. In brief, the VASP assay was used to
etermine the platelet reactivity index (PRI) (3,4). The
N-P2Y12 assay is a rapid whole blood point-of-care
evice that reports results as P2Y12 reaction units (PRU)
nd percent inhibition of platelet aggregation (%IPA) (3,4).
he LTA was performed after 5 mol/l and 20 mol/l
adenosine diphosphate stimuli, and results were reported as
percentage maximum platelet aggregation (3,4).
Statistical analysis. Conformity to the normal distribution
was evaluated for continuous variables with the Kolmogorov-
Smirnov test. For baseline characteristics, continuous variables
were expressed as mean  SD, and categorical variables were
expressed as frequencies and percentages. A repeated measures
analysis of variance (ANOVA) model was used to evaluate the
primary endpoint and all other intragroup comparisons. An
analysis of covariance (ANCOVA) method with a general
linear model, using the baseline value of the corresponding
platelet function test as a covariate, was used to evaluate all
exploratory between-groups comparisons. No adjustments for
multiple comparisons were made. Results are reported as
least-square mean  SEM for the detailed analyses. Missing
data were not imputed. In addition, p values for trend analyses
to assess platelet reactivity when increasing loading dose (10
mg, 30 mg, and 60 mg) was performed with a polynomial
contrast with the ANOVA method, considering loading dose
as a categorical variable with an ordinal scale. A 2-tailed p value
of 0.05 was considered to indicate a statistically significant
ifference for all the analyses performed. Statistical analysis was
erformed using SPSS version 16.0 software (SPSS Inc.,
hicago, Illinois).
The primary endpoint was the comparison of PRI values
etween baseline and 4 h after reloading with 60 mg of
rasugrel. Assuming a standard deviation of 18%, we would
e able to detect an intragroup difference of 15% in PRI
ith 20 patients, with 90% power and a 2-tailed alpha value
0.05. The same sample size was used for the exploratory
nalyses performed in the 10 mg and 30 mg arms. Thus,
onsidering a dropout rate of approximately of 8%, random-
Figure 1 Study Design
PCI  percutaneous coronary intervention.
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May 8, 2012:1681–7 Prasugrel Reload in Patients on Chronic Therapyization of as many as 65 patients was allowed to ensure that
complete pharmacodynamic data from 20 patients in each
group were available for analysis.
Results
Seventy-seven patients on maintenance prasugrel therapy
were screened. Of these, 65 were randomized; 1 patient was
withdrawn after randomization due to anemia identified
after baseline blood sampling. Therefore, 64 patients (10
Figure 2 Subject Disposition
Baseline Characteristics and Laboratory DataTable 1 Baseline Characteristics and Labor
Variable 10 mg (n  22)
Age, yrs 56.00 7.46
Male 16 (72.7%)
Obesity, BMI 30 kg/m2 10 (45.5%)
Race
Caucasian 18 (81.8%)
African-American 4 (18.2%)
Asian 0 (0%)
Hypertension 21 (100%)
Dyslipidemia 21 (100%)
Current smoking 8(36.4%)
Diabetes mellitus 6 (28.5%)
Prior CABG 6 (27.3%)
Medications
Beta-blockers 20 (91%)
ACEI/ARB 19 (90.5%)
Statins 18 (81.8%)
PPI 4 (18.2%)
CCB 3 (16.7%)
Nitrates 8 (38.1%)
LVEF, % 51.83 9.45
Creatinine, g/dl 0.92 0.30
Hematocrit, % 38.25 4.83
Platelet count, 1,000/mm3 215.50 43.42
Values are mean  SD or frequencies (%).
ACEI  angiotensin-converting enzyme inhibitor; ARB  angiotensin-recep
graft surgery; CCB  calcium-channel blocker; LVEF  left ventricle ejectionmg; n  22; 30 mg, n  21; and 60 mg, n  21) completed
the study. Patient disposition is illustrated in Figure 2.
Baseline characteristics are described in Table 1. No bleed-
ing complications or other adverse events were observed up
to 7 days after study termination.
There were no differences in baseline PRI between
groups (p  0.577). Intragroup comparisons showed that
PRI significantly reduced after a 60 mg and 30 mg prasugrel
dose, but not with a 10 mg dose. In particular, prasugrel
Data
mg (n  21) 60 mg (n  21) p Value
4.38 7.73 52.10 9.50 0.315
13 (61.9%) 18 (85.7%) 0.115
8 (38.1%) 14 (66.7%) 0.157
0.660
15 (71.4%) 15 (71.4%)
5 (23.8%) 6 (25.8%)
1 (4.8%) 0 (0%)
20 (95.2%) 21 (100%) 0.380
20 (95.2%) 21 (100%) 0.371
7(33.3%) 6 (28.6%) 0.341
8 (38.1%) 6 (30.0%) 0.382
1 (4.8%) 2 (10.0%) 0.094
17 (85%) 21 (100%) 0.214
17 (85%) 20 (95%) 0.568
19 (90.4%) 21 (100%) 0.871
1 (5%) 2 (10%) 0.396
1 (5%) 2 (10%) 0.509
4 (20%) 5 (24%) 0.409
6.39 13.60 54.21 9.10 0.092
0.84 0.29 0.92 0.20 0.596
9.24 5.07 40.00 4.38 0.567
1.39 97.02 233.28 40.50 0.136atory
30
5
4
3
26tor blocker; BMI  body mass index; CABG  coronary artery bypass
fraction; PPI  proton-pump inhibitor.
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0.001 between baseline and 4 h; p  0.002 between 1 h and
4 h). Similarly, prasugrel 30 mg reduced PRI levels at 1 h
(p  0.006) and 4 h (p  0.001, between baseline and 4 h;
p  0.044 between 1 h and 4 h). However, the use of
prasugrel 10 mg was associated with a nonsignificant reduc-
tion in PRI, at 1 h (p  0.355) and at 4 h (p  0.776 from
baseline; p  0.458 between 1 h and 4 h). Intergroup
comparisons showed that at 1 h after dosing, PRI levels
Figure 3 PRI Values Across Timepoints
The platelet reactivity index (PRI) values across timepoints (%) are expressed
as least-square means (LSM). Error bars indicate SEM. The p values for trend
analyses at each timepoint are provided. Yellow triangles  60 mg loading
dose of prasugrel; pink squares  30 mg loading dose; and blue diamonds 
10 mg dose of prasugrel.
Intragroup Pharmacodynamic AnalysisTable 2 Intragroup Pharmacodynamic Analysis
Pharmacodynamic Analysis Baseline 1 h
VASP PRI (%) 10 mg 31.6 3.3 26.5 3.1
30 mg 29.5 3.5 17.8 3.2
60 mg 26.6 3.4 11.5 3.2
VN PRU 10 mg 103.0 16.8 100.1 8.2
30 mg 97.6 17.2 51.7 8.4
60 mg 100.2 17.6 24.3 8.6
VN %IPA 10 mg 69.0 5.0 70.8 2.4
30 mg 69.2 5.1 85.6 2.4
60 mg 68.1 5.2 93.2 2.5
MPA 20 ADP 10 mg 37.0 3.4 33.4 1.8
30 mg 34.1 3.5 25.7 1.8
60 mg 36.7 3.6 23.8 1.8
MPA 5 ADP 10 mg 25.5 3.1 23.7 1.4
30 mg 25.1 3.2 17.7 1.5
60 mg 27.9 3.2 15.6 1.5Values are least-square mean  SEM. The p values were obtained using repeated measures analysis of
ADP  adenosine diphosphate; %IPA  percentage inhibition of platelet aggregation; MPA  maximawere reduced significantly using 60 mg, whereas there was a
large, but nonsignificant, decrease with a 30 mg versus a 10
mg dose (p 0.058); there were no significant differences in
PRI levels between 60 mg and 30 mg at 1 h (p 0.171). At
4 h after dosing, 60 mg and 30 mg continued to have lower
PRI levels than 10 mg (60 mg vs. 10 mg, p  0.001; 30 mg
vs. 10 mg, p  0.001); in addition, 60 mg prasugrel was
associated with lower PRI compared with 30 mg (p 0.05).
Trend analyses observed better platelet inhibitory effects
with higher prasugrel doses at both 1 h and 4 h (Fig. 3).
Similar results were observed with the VN-P2Y12 assay.
Intragroup comparisons showed enhanced platelet inhibi-
tory effects with prasugrel 60 mg and 30 mg, as measured by
both PRU and %IPA, at 1 h and 4 h (Table 2). Prasugrel 10
mg was associated with modest platelet inhibitory effects,
which reached statistical significance at 4 h. Intergroup
comparisons showed that prasugrel 60 mg and 30 mg doses
had lower PRU and higher %IPA at 1 h and 4 h after dosing
compared with prasugrel 10 mg. Prasugrel 60 mg was
associated with significantly lower PRU and higher %IPA
levels compared with 30 mg at 1 h. Although platelet
inhibitory effects increased over time with the 60 mg and 30
mg doses, the differences in PRU and %IPA were no longer
statistically significant at 4 h (Figs. 4A and 4B).
Similar to VN-P2Y12 testing, intragroup comparisons
showed marked platelet inhibitory effects as assessed by
LTA with prasugrel 60 mg and 30 mg at 1 h and 4 h, and
modest effects—which, however, reached statistical signifi-
cance at 4 h—with prasugrel 10 mg (Table 2). Intergroup
comparisons showed that prasugrel 60 mg and 30 mg both
achieved greater reduction in maximal percentage platelet
aggregation compared with 10 mg at 1 h and 4 h. Although
prasugrel 60 mg was associated with lower platelet reactivity
compared with 30 mg at both 1 h and 4 h, this did not reach
statistical significance (Figs. 5A and 5B).
p Values
4 h 4 h vs. Baseline 1 h vs. Baseline 4 h vs. 1 h
 2.8 0.776 0.355 0.458
 2.9 0.001 0.006 0.044
 2.7 0.001 0.004 0.002
 7.4 0.015 0.815 0.001
 7.6 0.001 0.001 0.004
 7.8 0.001 0.001 0.005
 2.2 0.006 0.258 0.001
 2.3 0.001 0.001 0.002
 2.3 0.001 0.001 0.069
 1.5 0.005 0.150 0.126
 1.6 0.001 0.001 0.076
 1.6 0.001 0.001 0.025
 1.2 0.006 0.285 0.243
 1.2 0.001 0.001 0.033
 1.3 0.001 0.001 0.08928.8
11.0
2.8
84.5
30.2
9.6
75.3
91.8
97.4
30.6
22.6
19.8
21.6
15.7
13.0variance.
l platelet aggregation; PRI  platelet reactivity index; VN  VerifyNow.
1685JACC Vol. 59, No. 19, 2012 Tello-Montoliu et al.
May 8, 2012:1681–7 Prasugrel Reload in Patients on Chronic TherapyDiscussion
The introduction into clinical practice of the third-
generation thienopyridine prasugrel has led to questions
about the optimal dosing regimen of this agent for patients
undergoing PCI who are already receiving chronic treat-
ment. In particular, concerns about the adequacy of platelet
inhibition if no additional load is given as well as the
potential for increased risk of bleeding with reloading have
Figure 4 VerifyNow P2Y12 Assay
(A) P2Y12 reaction units (PRU) values across timepoints. (B) Percentage inhibitio
means (LSM). Error bars indicate SEM. The p values for trend analyses at each tim
squares  30 mg loading dose; and blue diamonds  10 mg dose of prasugrel.
Figure 5 MPA Across Timepoints
(A) Maximum platelet aggregation (MPA) to 20 mol/l adenosine diphosphate. (B
means (LSM). Error bars indicate SEM. The p values for trend analyses at each tim
squares  30 mg loading dose; and blue diamonds  10 mg dose of prasugrel.emerged. A parallel scenario came forward several years ago
for patients on a regimen of chronic clopidogrel therapy
who were undergoing PCI (5,6). The present investigation
is novel in that it evaluates the pharmacodynamic impact of
different prasugrel dosing regimens on patients receiving
chronic prasugrel therapy. Patients were randomly allocated
to 3 different regimens, and findings showed that the use of
a 30 mg or 60 mg dose of prasugrel was associated with
atelet aggregation across timepoints. Values are expressed as least-square
t are provided. Yellow triangles  60 mg loading dose of prasugrel; pink
to 5 mol/l adenosine diphosphate. Values are expressed as least-square
t are provided. Yellow triangles  60 mg loading dose of prasugrel; pinkn of pl
epoin) MPA
epoin
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of the study compared with a 10 mg dose, for which only
modest effects were observed. Importantly, these effects
occurred rapidly, with significant differences observed 1 h
after dosing. Further, we observed that a 60 mg dosing
regimen was associated with enhanced platelet inhibition
compared with 30 mg at various timepoints when assessed
with P2Y12-specific assays. Ultimately, a 60 mg dose was
associated with rapid effects as demonstrated by the levels of
platelet reactivity achieved at 1 h, which were either similar
or greater than those achieved by a 30 mg dose at 4 h.
To date, various studies have assessed the pharmacody-
namic effects of prasugrel therapy in ACS patients who had
been already on treatment with clopidogrel and have dem-
onstrated that switching to prasugrel is associated with
enhanced platelet inhibition and that this can be achieved
more promptly (within 2 h) and with greater potency using
a 60 mg compared with a 10 mg dose (4,7). Although a
prasugrel 15 mg maintenance dose is associated with more
potent platelet inhibition compared with a 10 mg dose, this
increased minimal bleeding rates, which represents the
rationale for using 10 mg prasugrel (2,8). Overall, there is
evidence to suggest that there is room for further increase in
platelet inhibition in patients on 10 mg therapy after the
administration of a prasugrel loading dose, as confirmed in
this study. Moreover, more potent and prompt effects were
observed with a 60 mg dose compared with a 30 mg dose
when assessed by VASP-PRI and VN-P2Y12, but not with
LTA. These differences may be attributed to VASP-PRI
and VN-P2Y12 being more specific to assess the effects on
P2Y12 receptor signaling, while adenosine diphosphate
induced LTA results are more reflective of overall
purinergic-mediated platelet aggregation (9,10).
Platelet P2Y12 receptor blockade is pivotal in ACS
patients undergoing PCI (11). In clopidogrel-treated pa-
tients undergoing PCI, high platelet reactivity is associated
with ischemic events (9,10), suggesting the need for more
aggressive antithrombotic treatment, such as a reload, if
these patients undergo subsequent revascularization proce-
dures. Randomized studies showed clopidogrel reloading to
be associated with further platelet inhibition and a reduction
in ischemic events, including stent thrombosis (12,13).
Therefore, the results of the present pharmacodynamic
investigation using prasugrel may also have potential clinical
implications. Further, prasugrel-treated patients may still
present with high platelet reactivity, making them at risk for
atherothrombotic recurrences (14). These findings, as well
as the lower levels of platelet inhibition with prasugrel
during maintenance therapy compared with that achieved
after acute loading (3,4,7,8), support that patients on
chronic therapy may require additional dosing in the peri-
PCI setting. Although the optimal level of platelet inhibi-
tion required to minimize ischemic complications in pa-
tients undergoing PCI remains elusive, numerous studies
support the importance of enhanced platelet inhibition in
the peri-PCI period (9,10). Our observations showing thata 60 mg dose consistently showed more prompt and potent
platelet inhibitory effects by P2Y12 specific assays suggest the
potential for a clinical application of this dosing regimen for
patients on maintenance prasugrel therapy who require PCI.
Study limitations. This investigation was powered to as-
sess intragroup comparisons but not intergroup compari-
sons. Therefore, the latter results should be considered as
exploratory. In addition, our pharmacodynamic study was not
conducted in patients undergoing PCI and was not powered to
assess safety or efficacy. Hence, the lack of bleeding complica-
tions, including extrapolations to arterial access site complica-
tions, in this study should be interpreted with caution.
Conclusions
For patients on a maintenance prasugrel therapy regimen,
prasugrel reloading with a 60 mg dose is associated with
more rapid and enhanced platelet inhibition compared with
lower doses as assessed by P2Y12 specific assays. The clinical
implications of prasugrel reloading in patients on mainte-
nance prasugrel therapy undergoing PCI warrant further
investigation.
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